3rd Annual International Prostate Cancer and Urologic Oncology Symposium
SAVE THE DATE – DECEMBER 13 – 15, 2018
1468 Madison Avenue
New York, NY
Meet the Course Director
Dr. Ash Tewari, MBBS, MCh
Dr. Ash Tewari is an innovator in the fields of robotic prostate cancer surgery and prostate cancer treatment. He also designated various grades of nerve-sparing utilizing information from MRIs, allowing for incremental nerve-sparing particularly in cases that would have not previously qualified without this graded approach. He has described traction free and athermal nerve-sparing techniques and developed an innovative Detrusor wrap technique for early urinary continence.
Working with genitourinary pathologists and scientists from the University of Hamburg, he is currently evaluating the role of MRI-guided NeuroSAFE ® and sphinctersafe approaches in expanding opportunities for nerve-sparing. An active researcher and surgeon scientist, he is one of only a few robotic surgeons to be awarded a NIH R01 grant, for the investigation of real-time tissue identification during prostate cancer surgery.
Ketan Badani is the Vice Chairman of Urology and Director of the Robotic Surgery Program and Kidney Cancer Program at the Mount Sinai Health System in New York City. He has been the director of several large multi-organ robotic surgery programs over the past 10 years, and has an experience of over 5,000 robotic surgeries to date.
He joined University of Southern California in March 2009, prior to which he was at the Cleveland Clinic for almost 12 years from 1997-2009.
Sinai (ISMMS) and holds the Ward Coleman Chair in Cancer Research. Dr. Bhardwaj brings expertise in human immunology and a variety of immune therapies, having developed Toll Like Receptor (TLR) agonist- and dendritic cell based vaccines for the treatment of both cancer and infection in several Investigator-Initiated studies. Dr. Bhardwaj is an elected member of the American Society of Clinical Investigation and the American Association of Physicians, a recipient of the Doris Duke Distinguished Scientist Award and was named one of the Scientific American Magazine’s Top 50 Researchers, receiving the Award for Medical Research in 2004. She received the Fred W. All Award for new discoveries in Immunology in 2015 from The Cancer Research Institute. Dr. Bhardwaj is a senior editor of the AACR Cancer Immunology Research journal, senior editor for Frontiers in Immunology and consulting editor for the Journal of Clinical Investigation. She has also served on NIH Study Sections and multiple advisory councils. Dr. Bhardwaj was formally Chair of the Cancer Immunology Steering Committee of the AACR. Dr. Bhardwaj has also successfully acquired multiple federal and foundation grants and has authored over 200 publications.
Dr. Campbell obtained BS, MD, and PhD degrees at The University of Chicago and then did a Urology Residency at The Cleveland Clinic (1989-1995), which was followed by a fellowship in Urologic Oncology, at Memorial Sloan Kettering Cancer Center (1995-1996). Dr. Campbell’s primary interests have included renal cell carcinoma, bladder cancer, tumor angiogenesis, and urology residency training. He has served as Chair of the Exam Committee for the Society of Urologic Oncology and President for the Society of Pelvic Surgeons.
Dr. Campbell was recently Chair for the AUA Guidelines Panel for Management of Localized Kidney Cancer (2017), and was Co-Chair for the previous iteration of this in 2009. Dr. Campbell was Co-Editor of Renal Cell Carcinoma (BC Decker, 2009) and Editor of Renal Cell Carcinoma: Clinical Management (Humana Press, 2013) and 100 Questions and Answers about Kidney Cancer (Jones and Bartlett, 2008, 2012, and 2015). He has also authored or co-authored “Malignant Renal Tumors” for Campbell/Walsh Urology for the past 4 editions (2000, 2005, 2010, and 2015) and will be doing so again in 2017-2018. Over the past 4-5 years, Dr. Campbell’s academic work has focused on the role of PN and RN in the management of RCC, the determinants of functional recovery after PN, the survival implications of differences in renal function after renal cancer surgery, and the use of neoadjuvant TKI ‘s to enable PN and optimize functional outcomes.
Formerly the Chief of the Division of Urology (1992-2002) after his arrival at UC Irvine from the City of Hope in 1992, Dr. Ahlering became Chief of the Division of Urologic Oncology when the new Department of Urololgy was established in 2002. He majored in chemistry as an undergraduate at the University of California, Berkeley, then received his medical degree at St. Louis University School of Medicine, followed by a residency in urology at the University of Southern California in Los Angeles. He then completed a two-year fellowship in urologic oncology under the clinical training of Dr. Donald G. Skinner and laboratory training under Peter Jones, Ph.D. Dr. Ahlering became a member of the Society of Urologic Oncology in 1998; his clinical practice is devoted to urologic cancer. He has received local, national, and international recognition for his expertise in urologic oncology, in particular continent urinary diversion. His research focuses on the invasion and metastasis of prostate cancer, and development of minimally invasive radical prostatectomy assisted by the da Vinci robot. He has performed more than 1000 such robotic surgeries, including the first robotic prostatatectomy surgeries in Denmark, Australia, and Canada. Dr. Ahlering has active research projects in prostate and bladder cancer, and has produced over 85 publications of journal articles and book chapters. He is also a member of the editorial boards of the journals: Urology, and the Journal of Urology, and the Societies of the American Urological Association, and its Western Section Treasurer. As a commitment to public service, he has lectured at the American Cancer Society’s Prostate Cancer Awareness Forum in Southern California for the last four years. He was also an invited speaker at Senator Barbara Boxer’s Prostate Cancer Forum in 1996.